The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1

Lisa Derosa, Bertrand Routy, Guido Kroemer, Laurence Zitvogel

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    52 Citations (Scopus)

    Résumé

    Cancer immunotherapists have been searching for biomarkers predicting patient responses to PD-1/PD-L1 blockade in neoplastic cells as well as in the immune system. Now, accumulating evidence indicates that the composition of the intestinal microflora has a major impact on patient prognosis. Here, we enumerate the bacterial species that are associated with favorable outcome of immunotherapy.

    langue originaleAnglais
    Numéro d'articlee1434468
    journalOncoImmunology
    Volume7
    Numéro de publication6
    Les DOIs
    étatPublié - 3 juin 2018

    Contient cette citation